Vimal Drugs Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 18-06-2024
- Paid Up Capital ₹ 3.99 Cr
as on 18-06-2024
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 44.77 Cr
as on 18-06-2024
- Satisfied Charges ₹ 4.10 Cr
as on 18-06-2024
- Revenue -33.57%
(FY 2023)
- Profit -92.57%
(FY 2023)
- Ebitda -44.91%
(FY 2023)
- Net Worth 5.58%
(FY 2023)
- Total Assets 27.50%
(FY 2023)
About Vimal Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 3.99 Cr.
The company currently has active open charges totaling ₹44.77 Cr. The company has closed loans amounting to ₹4.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Satish Mallela, Vasireddy Devi, and Venkata Vasireddy serve as directors at the Company.
- CIN/LLPIN
U24100TG2009PTC063551
- Company No.
063551
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 May 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Vimal Drugs Private Limited offer?
Vimal Drugs Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Pain Balm & Ointments.
Who are the key members and board of directors at Vimal Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Vasireddy  | Director | 21-Nov-2015 | Current |
| Satish Mallela | Additional Director | 13-Apr-2021 | Current |
| Vasireddy Devi | Director | 17-Jan-2020 | Current |
Financial Performance of Vimal Drugs.
Vimal Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 33.57% decrease. The company also saw a substantial fall in profitability, with a 92.57% decrease in profit. The company's net worth moved up by a moderate rise of 5.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vimal Drugs?
In 2021, Vimal Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Feb 2024 | ₹10.00 Cr | Open |
Others Creation Date: 10 May 2022 | ₹1.10 Cr | Open |
Hdfc Bank Limited Creation Date: 01 Sep 2017 | ₹33.67 Cr | Open |
How Many Employees Work at Vimal Drugs?
Vimal Drugs has a workforce of 139 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vimal Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vimal Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
